Table II.

Results of the overall review of the ZJU and worldwide microarray datasets.

Dataset	ZJU	Ivshina	Wang	Pawitan	Desmedt	NKIb
No. of patients	223	249	286	159	198	295
Assessible casesa	128	213	253	159	158	295
Date of study	1999–2006	1987–1989	1980–1995	1994–1996	1980–1998	1984–1995
Microarray	N/A	Affimetrix	Affimetrix	Affimetrix	Affimetrix	Agilent
		HG-U133	HG-U133	HG-U133	HG-U133	25K Chip
Accession no.	N/A	GSE4922	GSE2034	GSE1456	GSE7390	N/A
SHMT2 fragments	N/A
214096_s_at	N/A	Y	Y	Y	Y	N/A
214095_at	N/A	Y	Y	Y	Y	N/A
214437_at	N/A	Y	Y	Y	Y	N/A
Age at diagnosis	Y	Y	N/A	N/A	Y	Y
Histological type	Y	N/A	N/A	N/A	Y	Y
Elson grade	Y	Y	N/A	Y	Y	Y
Tumor size	Y	Y	N/A	N/A	Y	Y
Lymph node	Y	Y	Y	N/A	Y	Y
Metastasis	Y	N/A	Y	N/A	Y	Y
TNM stage	Y	Y	N/A	N/A	Y	Y
ER status	Y	Y	Y	Y	Y	Y
PR status	Y	N/A	N/A	N/A	N/A	Y
HER2 status	Y	N/A	N/A	Y	N/A	Y
MKI67 status	Y	N/A	N/A	N/A	N/A	Y
P53 mutation	Y	Y	N/A	N/A	N/A	N
Molecular subtype	Y	N/A	N/A	Y	N/A	Y
Chemotherapy	Y	N/A	N/A	N/A	N/A	Y
Radiotherapy	Y	N/A	N/A	N/A	N/A	Y
Hormone therapy	Y	N/A	N/A	N/A	N/A	Y
OS monthsc (range)	8.9–104.9	N/A	N/A	2.2–101.9	4.9–303.6	1.0–220.1
PFS monthsd (range)	2.5–104.9	0–153.0	2.0–171.0	2.2–101.9	4–231.4	1.0–220.1

^aPatients without clinical information, follow-up data, or SHMT2 expression level were excluded from the present study.

^bNKI dataset used a 25,000-gene array (Agilent Technologies), which used the same fragments as Affymetrix HG-U133 array.

^cOS, overall survival;

^dPFS, progression-free survival; N/A, not available; Y, yes; N, no; SHMT2, serine hydroxylmethyltransferase 2.